Cargando…
A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy
Metaplastic breast cancer is a rare and often chemo-refractory subtype of breast cancer with poor prognosis and limited treatment options. Recent studies have reported overexpression of programmed death ligand 1 (PD-L1) in metaplastic breast cancers, and there are several reports of anti-PD-1/L1 bei...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217650/ https://www.ncbi.nlm.nih.gov/pubmed/34168978 http://dx.doi.org/10.3389/fonc.2021.635237 |
_version_ | 1783710636185747456 |
---|---|
author | Kim, Isaac Rajamanickam, Venkatesh Bernard, Brady Chun, Brie Wu, Yaping Martel, Maritza Sun, Zhaoyu Redmond, William L. Sanchez, Katherine Basho, Reva McArthur, Heather Page, David B. |
author_facet | Kim, Isaac Rajamanickam, Venkatesh Bernard, Brady Chun, Brie Wu, Yaping Martel, Maritza Sun, Zhaoyu Redmond, William L. Sanchez, Katherine Basho, Reva McArthur, Heather Page, David B. |
author_sort | Kim, Isaac |
collection | PubMed |
description | Metaplastic breast cancer is a rare and often chemo-refractory subtype of breast cancer with poor prognosis and limited treatment options. Recent studies have reported overexpression of programmed death ligand 1 (PD-L1) in metaplastic breast cancers, and there are several reports of anti-PD-1/L1 being potentially active in this disease. In this case series, we present 5 patients with metastatic metaplastic breast cancer treated with anti-PD-1-based therapy at a single center, with 3 of 5 cases demonstrating a response to therapy, and one of the responding cases being a metaplastic lobular carcinoma with low-level hormone receptor expression. Cases were evaluated for PD-L1 expression, tumor infiltrating lymphocytes (TILs), DNA mutations, RNA sequencing, and T-cell receptor sequencing. Duration of the response in these cases was limited, in contrast to the more durable responses noted in other recently published reports. |
format | Online Article Text |
id | pubmed-8217650 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82176502021-06-23 A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy Kim, Isaac Rajamanickam, Venkatesh Bernard, Brady Chun, Brie Wu, Yaping Martel, Maritza Sun, Zhaoyu Redmond, William L. Sanchez, Katherine Basho, Reva McArthur, Heather Page, David B. Front Oncol Oncology Metaplastic breast cancer is a rare and often chemo-refractory subtype of breast cancer with poor prognosis and limited treatment options. Recent studies have reported overexpression of programmed death ligand 1 (PD-L1) in metaplastic breast cancers, and there are several reports of anti-PD-1/L1 being potentially active in this disease. In this case series, we present 5 patients with metastatic metaplastic breast cancer treated with anti-PD-1-based therapy at a single center, with 3 of 5 cases demonstrating a response to therapy, and one of the responding cases being a metaplastic lobular carcinoma with low-level hormone receptor expression. Cases were evaluated for PD-L1 expression, tumor infiltrating lymphocytes (TILs), DNA mutations, RNA sequencing, and T-cell receptor sequencing. Duration of the response in these cases was limited, in contrast to the more durable responses noted in other recently published reports. Frontiers Media S.A. 2021-06-08 /pmc/articles/PMC8217650/ /pubmed/34168978 http://dx.doi.org/10.3389/fonc.2021.635237 Text en Copyright © 2021 Kim, Rajamanickam, Bernard, Chun, Wu, Martel, Sun, Redmond, Sanchez, Basho, McArthur and Page https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Kim, Isaac Rajamanickam, Venkatesh Bernard, Brady Chun, Brie Wu, Yaping Martel, Maritza Sun, Zhaoyu Redmond, William L. Sanchez, Katherine Basho, Reva McArthur, Heather Page, David B. A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy |
title | A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy |
title_full | A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy |
title_fullStr | A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy |
title_full_unstemmed | A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy |
title_short | A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy |
title_sort | case series of metastatic metaplastic breast carcinoma treated with anti-pd-1 therapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217650/ https://www.ncbi.nlm.nih.gov/pubmed/34168978 http://dx.doi.org/10.3389/fonc.2021.635237 |
work_keys_str_mv | AT kimisaac acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT rajamanickamvenkatesh acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT bernardbrady acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT chunbrie acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT wuyaping acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT martelmaritza acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT sunzhaoyu acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT redmondwilliaml acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT sanchezkatherine acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT bashoreva acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT mcarthurheather acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT pagedavidb acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT kimisaac caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT rajamanickamvenkatesh caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT bernardbrady caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT chunbrie caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT wuyaping caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT martelmaritza caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT sunzhaoyu caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT redmondwilliaml caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT sanchezkatherine caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT bashoreva caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT mcarthurheather caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy AT pagedavidb caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy |